Catalyst
Slingshot members are tracking this event:
Alexion (ALXN) Plans to Initiate a Phase 3 Trial of ALXN1210 in Pediatric Patients With Atypical Hemolytic Uremic Syndrome (aHUS) in 2017
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| ALXN |
|
|
||||
Additional Information
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jan 06, 2017
Occurred Source:
http://news.alexionpharma.com/press-release/company-news/fda-grants-orphan-drug-designation-alxn1210-treatment-patients-paroxysmal
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Phase 3, Alxn1210, Trial Initiation, Atypical Hemolytic Uremic Syndrome, Ahus
